Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
Abbreviations
sabatolimab - TIM3 antagonist
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
Target Patients
Read-out Milestone(s)
Publication
NCT03946670 STIMULUS MDS-1 (CMBG453B12201)
Myelodysplastic syndrome
Phase 2
120
Complete Remission (CR) rate and Progression Free Survival (PFS)
Experimental: Sabatolimab (MBG453) + hypomethylating agents
Placebo comparator: Placebo + hypomethylating agents
Adult subjects with intermediate, high or very high risk Myelodysplastic Syndrome
(MDS) as per IPSS-R criteria
2022-2023
TBD
NCT04150029 STIMULUS-AML1 (CMBG453C12201)
Unfit acute myeloid leukaemia
Phase 2
86
Incidence of dose limiting toxicities (Safety run-in patients only)
Percentage of subjects achieving complete remission (CR)
Single arm safety and efficacy study of sabatolimab in combination with azacitidine
and venetoclax
Newly diagnosed adult AML patients who are not suitable for treatment with
intensive chemotherapy
2023
TBD
138 Investor Relations | Q4 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation